Quite an interesting little company. Two clinical programs (Ph1b/2a) ongoing (US Govt funded), 2-3 more to commence in early 2016.. and has a MC of $4mil. QUite amazing.. any positive interim data out of those trials and this easily could be a 5-10 bagger very quickly.. worth the risk reward ration IMHO. Difficulty now is trying to accumulate without moving the market too much
